FTRE vs LKFT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
FTRE · Fortrea Holdings$21.96 ▲ 7.33%
LKFT · Lakefront Biotherapeutics$33.45 ▼ 0.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- FTRE +96.4%
- LKFT +3.1%
Head to head
| Metric | FTRE | LKFT |
|---|---|---|
| Price | $21.96 | $33.45 |
| Change today | ▲ 7.33% | ▼ 0.33% |
| Market cap | $2.12B | $2.20B |
| Return, 3 months | +15.6% | +24.3% |
| Return, year to date | +27.3% | +2.3% |
| Return, 1 year | +95.2% | +6.1% |
| P/E (TTM) | – | 3.3 |
| P/B | 4.0 | 0.6 |
| P/E percentile vs own 5y | 13th | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -1.4% | -81.5% |
| Net profit growth (YoY) | +103.8% | +102.0% |
| Gross margin | 20.0% | 97.5% |
| Operating margin | 1.7% | 61.6% |
| Net margin | -2.6% | 60.2% |
| Return on equity | -12.3% | 20.2% |
| Analyst target vs. price | +16.4% | +12.1% |
| Analyst buy share | 70% | 50% |
| RSI (14) | 51 | 69 |
| 30-day volatility | 64.9% | 26.9% |
| Max drawdown, 1 year | -51.8% | -24.7% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LKFT is the largest of the group by market value.
- FTRE has returned the most over the past year.
- FTRE is growing revenue fastest.
- LKFT keeps the most profit per dollar of sales.
- LKFT has been the calmest stock over the last 30 days.